NCT07187440Toboroz
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
A Prospective, Multi-center, Observational Study to Evaluate the Clinical Outcomes of Agalsidase Alfa Enzyme Replacement Therapy Among Chinese Patients With Fabry Disease in Real-world Clinical Practice
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jan. 2.
Rövid összefoglaló (regiszter, angolul)
Fabry Disease is a rare blood disorder that some people are born with. People with Fabry disease have low levels of an enzyme called alpha-galactosidase A. This enzyme helps to cut down fat-like substances. Without alpha-galactosidase A, large forms of these substances build up and clot in blood vessels. Over time, this can affect vital organs (especially the heart, kidneys, and brain) causing serious health problems with advancing age. Agalsidase alfa (Replagal®) is a human enzyme made in the laboratory and may provide higher levels of alpha-galactosidase A. Replagal® works the same way as natural alpha-galactosidase A does. The main aim of this study is to learn more about the treatment with Replagal® in Chinese children and adults with Fabry disease. The study aims to assess the heart and kidney function in people with Fabry disease who are routinely treated with Replagal®. Other aims are to learn about the change in heart and kidney function, impact on quality of life, how the treatment with Replagal® works for people with Fabry Disease, and how safe the treatment with Replagal® is in routine real-world settings. Participants will receive with Replagal® per the routine treatment settings in China. No study-specific visits to the clinical are scheduled.
- Állapot (regiszter)
- Toboroz
- Vizsgálattípus
- Megfigyeléses
- Résztvevők száma
- 200 (tervezett)
- Első benyújtás
- 2025. szept. 18.
- Kezdés
- 2025. nov. 1.
- Elsődleges befejezés
- 2028. nov. 30.
- Fő szponzor
- Takeda
- Betegségek
- Fabry-betegség
- NCT-szám
- NCT07187440
Mit vállalsz
- Vizsgálat típusa: Megfigyeléses
- Tervezett résztvevők: 200
- 2025. nov. 1. és az elsődleges befejezés (2028. nov. 30.) között
- 18 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- Participant will be excluded if they have documented New York Heart Association (NYHA) functional Class IV heart failure symptoms (Implantable cardioverter-defibrillator [ICD] implanted excluded), third-degree atrioventricular block (ICD implanted excluded), acute myocardial infarction within the last 3 months and severe stroke (NIH Stroke Scale [NIHSS] >= to 21).
- Participant has enrolled in Fabry disease interventional clinical trial currently.
Egyéb
- Other situations that the investigator considers not suitable for participation in this study.
Kiket keres a vizsgálat
- Participants who meet all of the following criteria are eligible for this study:
- Participant is greater than or equal to (>= 7) years old.
- Participant with confirmed diagnosis of Fabry disease (by investigator).
- Participant never received or has received ERT (agalsidase alfa or agalsidase beta) within 12 weeks at most prior to enrolment.
- Participant who will receive ERT with agalsidase alfa in routine clinical practice settings.
- For >= 18 years old, participant should sign the informed consent form (ICF); for 8-17 years old, participant and his (her) parents/ legally authorized representative (LAR) should both sign the ICF; for < 8 years old, participant will give assent and his (her) parents/legally authorized representative should sign the ICF accordingly.
Életkor a regiszterben: 7 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (18)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Peking University Third Hospital | Beijing | Kína | Toboroz |
| Peking University First Hospital | Beijing | Kína | Toborzás még nem indult |
| Peking Union Medical College Hospital | Beijing | Kína | Toboroz |
| West China Hospital of Sichuan University | Chengdu | Kína | Toborzás még nem indult |
| Fuzhou University Provincial Affiliated Hospital | Fuzhou | Kína | Toboroz |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou | Kína | Toborzás még nem indult |
| The Second Affiliated Hospital of Harbin Medical University | Harbin | Kína | Toborzás még nem indult |
| The First Affiliated Hospital of USTC(Anhui Provincial Hospital) | Hefei | Kína | Toborzás még nem indult |
| Affiliated Drum Tower Hospital, Medical School of Nanjing University | Nanjing | Kína | Toboroz |
| The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital | Nanjing | Kína | Toborzás még nem indult |
| Shantou Central Hospital | Shantou | Kína | Toboroz |
| The University of Hong Kong-Shenzhen Hospital | Shenzhen | Kína | Toborzás még nem indult |
| The Second Hospital of Hebei Medical University | Shijiazhuang | Kína | Toboroz |
| The First Affiliated Hospital of Soochow University | Suzhou | Kína | Toboroz |
| Second hospital of Shanxi Medical University | Taiyuan | Kína | Toborzás még nem indult |
| Tianjin Chest Hospital | Tianjin | Kína | Toborzás még nem indult |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Xi'an | Kína | Toboroz |
| The First Affiliated Hospital of Xi'an Jiaotong University | Xi’an | Kína | Toborzás még nem indult |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.